|DB00012||Darbepoetin alfa||For the treatment of anemia (from renal transplants or certain HIV treatment)|
|DB00016||Erythropoietin||Indicated in adult and paediatric patients for the:
- treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis.
- treatment of anemia due to zidovudine in patients with HIV-infection.
- treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
- reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.|
|DB00019||Pegfilgrastim||Pegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection. It is also indicated to increase in patients with acute myelosuppresive radiation exposure.|
|DB00020||Sargramostim||For the treatment of cancer and bone marrow transplant|
|DB00055||Drotrecogin alfa||For reduction of mortality in patients with severe sepsis.|
|DB00058||Alpha-1-proteinase inhibitor||For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.|
|DB00099||Filgrastim||This drug is a leucocyte growth factor [FDA label] indicated to:
Decrease the incidence of infection‚ as manifested by febrile neutropenia‚
in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [FDA label].
Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment in patients with acute myeloid leukemia (AML) [FDA label]
Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) [FDA label]
Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [FDA label]
Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia [FDA label].
Neupogen is approved for treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident [L3739].|
|DB00290||Bleomycin||For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.|
|DB00512||Vancomycin||A variety of dosage forms (for example, oral, injections, etc.) exist for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci [FDA Label].
Additionally, a unique FDA approved oral liquid treatment is also available and indicated for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [L1196].|
|DB01584||Thyroglobulin||For the treatment of hypothyroidism (deficiency in the production of thyroid hormone).|
|DB04911||Oritavancin||Indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.|
|DB04933||Eritoran||Investigated for use/treatment in sepsis and septicemia.|
|DB05006||Adecatumumab||Investigated for use/treatment in breast cancer and prostate cancer.|
|DB05332||Romiplostim||Treatment of chronic immune thrombocytopenic purpura. |
|DB05446||LJP 1082||Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.|
|DB05718||Maxy-G34||Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.|
|DB05735||Cefilavancin||Investigated for use/treatment in bacterial infection, skin infections/disorders, and staph bacterial infections.|
|DB05777||Thrombomodulin Alfa||Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.|
|DB05793||PRO-542||Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.|
|DB05931||Pegdinetanib||Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.|
|DB06149||Teicoplanin||For the treatment of bacterial infections caused by susceptible microorganisms.|
|DB06219||Dalbavancin||Dalbavancin for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus) and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356].
Dalbavancin is not active against gram-negative bacteria; therefore, combination therapy may be clinically indicated if the ABSSSI is polymicrobial and includes a suspected or documented gram-negative pathogen [F2356].
To reduce the development of drug-resistant bacteria and maintain the effectiveness of dalbavancin and other antibacterial drugs, dalbavancin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria [FDA Label, F2356]. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy [FDA Label, F2356]. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy [FDA Label, F2356]. |
|DB06404||Human C1-esterase inhibitor||For routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).|
|DB06447||E5531||Investigated for use/treatment in sepsis and septicemia.|
|DB06534||Thrombopoietin||Investigated for use/treatment in thrombocytopenia.|
|DB06584||TG4010||Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.|
|DB09107||Methoxy polyethylene glycol-epoetin beta||For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.|
|DB09349||Gastric intrinsic factor||Intrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias responsive to oral iron therapy. |
|DB11312||Protein C||Protein C Concentrate is indicated for pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.|
|DB11624||Epoetin delta||Not Available|
|DB12992||Bleomycin A6||Not Available|
|DB13144||Lenograstim||The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy.
Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy.
Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion.
GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome).|
|DB13149||Protein S human||For use in the emergency reversal of coagulation factor deficiency in patients recieving vitamin K antagonist therapy [FDA Label]. Protein S is administered as part of a cocktail containing several other coagulation factors.|
|DB13200||Lipegfilgrastim||Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) [L2441]. |
|DB13257||Ferrous sulfate anhydrous||For the prevention and treatment of iron deficiency anemia [L2252].
|DB13615||Mifamurtide||Indicated in children, adolescents and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection, typically in combination with post-operative multi-agent chemotherapy [L1203].|
|DB14111||Ceramide NP||Not Available|
|DB14705||Ceramide AP||Not Available|
|DB14706||Ceramide NG||Not Available|
|DB05386||Regramostim||Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.|
|DB15015||Recombinant CD40-ligand||Not Available|